Printer Friendly

Citizens Financial announces preferred stock dividends.

M2 EQUITYBITES-November 18, 2019-Citizens Financial announces preferred stock dividends

(C)2019 M2 COMMUNICATIONS http://www.m2.com

The board of directors of Citizens Financial Group Inc (NYSE:CFG) authorised cash dividends on the company's series B, C, D and E fixed-to-floating non-cumulative perpetual preferred stock, the company revealed on Saturday.

Accordingly, a half yearly dividend of USD30.00 per share will be plaid on the company's 6.000% fixed-to-floating non-cumulative perpetual preferred stock, series B; a quarterly dividend of USD15.9375 per share on its 6.375% fixed-to-floating non-cumulative perpetual preferred stock, series C; a quarterly dividend of USD15.875 per share (USD0.396875 per depositary share, each representing a 1/40th interest in a share of the preferred stock) on its 6.350% fixed-to-floating non-cumulative perpetual preferred stock, series D; and a quarterly dividend of USD9.444 per share (USD0.236111111 per depositary share, each representing a 1/40th interest in a share of the preferred stock) on its 5.000% fixed-to-floating non-cumulative perpetual preferred stock, series E.

All of the dividends will be paid on 6 January 2020 to the respective shareholders of record date at the close of business on 20 December 2019.

Citizens Financial is a financial institution with USD164.4bn in assets as of 30 September 2019. It offers a broad range of retail and commercial banking products and services and is headquartered in Providence, Rhode Island, USA.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 18, 2019
Words:244
Previous Article:Novartis wins FDA approval of Adakveo to reduce frequency of pain crises in sickle cell disease patients.
Next Article:The FDA authorises marketing of duodenoscopes with disposable elevator component for use with endoscopic devices.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |